This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Epizyme Future Growth

Future criteria checks 2/6

Key information

15.8%

Earnings growth rate

16.6%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	37.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	n/a

Recent future growth updates

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12

Epizyme Q3 2020 Earnings Preview

Nov 05

Earnings and Revenue Growth Forecasts

NasdaqGS:EPZM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	136	-173	N/A	N/A	3
12/31/2023	80	-196	N/A	N/A	4
12/31/2022	49	-182	N/A	N/A	4
6/30/2022	53	-208	-209	-209	N/A
3/31/2022	38	-236	-211	-210	N/A
12/31/2021	37	-251	-227	-227	N/A
9/30/2021	34	-267	-229	-228	N/A
6/30/2021	33	-257	-229	-228	N/A
3/31/2021	22	-251	-250	-224	N/A
12/31/2020	16	-232	-257	-206	N/A
9/30/2020	12	-222	-239	-189	N/A
6/30/2020	14	-202	-235	-184	N/A
3/31/2020	17	-192	-200	-174	N/A
12/31/2019	24	-173	-148	-147	N/A
9/30/2019	29	-140	-135	-134	N/A
6/30/2019	23	-141	-132	-132	N/A
3/31/2019	30	-122	-123	-123	N/A
12/31/2018	22	-124	-122	-122	N/A
9/30/2018	12	-137	-130	-129	N/A
6/30/2018	12	-137	-133	-133	N/A
3/31/2018	10	-136	-119	-118	N/A
12/31/2017	10	-134	-121	-120	N/A
9/30/2017	10	-133	-112	-111	N/A
6/30/2017	17	-120	-98	-97	N/A
3/31/2017	8	-120	-105	-104	N/A
12/31/2016	8	-110	-97	-96	N/A
9/30/2016	8	-97	-97	-97	N/A
6/30/2016	2	-96	-80	-79	N/A
3/31/2016	2	-94	N/A	-76	N/A
12/31/2015	3	-132	N/A	-73	N/A
9/30/2015	12	-125	N/A	-72	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EPZM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EPZM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EPZM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EPZM's revenue (37.6% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: EPZM's revenue (37.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EPZM's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Epizyme Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 12%

Price target decreased to US$6.60

Consensus forecasts updated

Price target decreased to US$9.02

Price target decreased to US$9.20

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Recent updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Epizyme Acquisition By Ipsen: CVR Value

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Receives Non-Compliance Letter from Nasdaq

Epizyme Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 12%

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$6.60

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Epizyme, Inc. has completed a Follow-on Equity Offering in the amount of $85.000001 million.

Price target decreased to US$9.02

Price target decreased to US$9.20

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Price target increased to US$12.25

Consensus revenue estimates increase by 19%

Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Epizyme, Inc. to Present New Data from Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

Epizyme: Taking Advantage Of Recent Sell-Off

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Director Kevin Conroy has joined 4th company board

Consensus revenue estimates increase to US$53.4m

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

Price target decreased to US$11.14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 3000E Value Index

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Independent Chairman recently bought US$500k worth of stock

Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Analysts lower revenue estimates to US$49.1m

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Full year 2020 earnings released: US$2.30 loss per share (vs US$1.93 loss in FY 2019)

Price target lowered to US$21.25

Revenue and earnings beat expectations

Epizyme, Inc. Provides Update on Clinical Trials

New 90-day low: US$10.67

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Independent Director recently bought US$60k worth of stock

Price target lowered to US$23.50

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue and earnings miss expectations

Analysts update estimates

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue and earnings miss expectations

Epizyme, Inc. Announces Executive Promotions

New 90-day low: US$10.34

Epizyme Q3 2020 Earnings Preview

Epizyme Announces Two Lancet Oncology Publications on TAZVERIK Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

New 90-day low: US$11.52

New 90-day low - US$12.00

New 90-day low - US$12.13

First half earnings released

New 90-day low - US$13.84